Mariana Baz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2983989/publications.pdf

Version: 2024-02-01

50 papers	2,018 citations	279487 23 h-index	243296 44 g-index
51 all docs	51 docs citations	51 times ranked	2561 citing authors

#	Article	IF	Citations
1	Emergence of Oseltamivir-Resistant Pandemic H1N1 Virus during Prophylaxis. New England Journal of Medicine, 2009, 361, 2296-2297.	13.9	204
2	Characterization of Multidrug-Resistant Influenza A/H3N2 Viruses Shed during 1 Year by an Immunocompromised Child. Clinical Infectious Diseases, 2006, 43, 1555-1561.	2.9	174
3	Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine, 2008, 26, 3395-3403.	1.7	172
4	Impact of Neuraminidase Mutations Conferring Influenza Resistance to Neuraminidase Inhibitors in the N1 and N2 Genetic Backgrounds. Antiviral Therapy, 2006, 11, 971-976.	0.6	155
5	Effect of the Neuraminidase Mutation H274Y Conferring Resistance to Oseltamivir on the Replicative Capacity and Virulence of Old and Recent Human Influenza A(H1N1) Viruses. Journal of Infectious Diseases, 2010, 201, 740-745.	1.9	116
6	Household Transmission of the 2009 Pandemic A/H1N1 Influenza Virus: Elevated Laboratoryâ€Confirmed Secondary Attack Rates and Evidence of Asymptomatic Infections. Clinical Infectious Diseases, 2010, 51, 1033-1041.	2.9	102
7	Oseltamivir-Resistant Pandemic A/H1N1 Virus Is as Virulent as Its Wild-Type Counterpart in Mice and Ferrets. PLoS Pathogens, 2010, 6, e1001015.	2.1	85
8	H5N1 vaccines in humans. Virus Research, 2013, 178, 78-98.	1.1	83
9	Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antiviral Therapy, 2006, 11, 971-6.	0.6	81
10	Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Research, 2007, 74, 159-162.	1.9	61
11	Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Research, 2008, 77, 163-166.	1.9	59
12	Development of a High-Yield Live Attenuated H7N9 Influenza Virus Vaccine That Provides Protection against Homologous and Heterologous H7 Wild-Type Viruses in Ferrets. Journal of Virology, 2014, 88, 7016-7023.	1.5	57
13	Structural Insight into NS5 of Zika Virus Leading to the Discovery of MTase Inhibitors. Journal of the American Chemical Society, 2016, 138, 16212-16215.	6.6	52
14	Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains. Journal of Infectious Diseases, 2020, 221, 63-70.	1.9	51
15	Antiviral Agents in Development for Zika Virus Infections. Pharmaceuticals, 2019, 12, 101.	1.7	50
16	Nonreplicating Influenza A Virus Vaccines Confer Broad Protection against Lethal Challenge. MBio, 2015, 6, e01487-15.	1.8	48
17	Effects of Different Adjuvants in the Context of Intramuscular and Intranasal Routes on Humoral and Cellular Immune Responses Induced by Detergent-Split A/H3N2 Influenza Vaccines in Mice. Vaccine Journal, 2012, 19, 209-218.	3.2	42
18	A Novel Neuraminidase Deletion Mutation Conferring Resistance to Oseltamivir in Clinical Influenza A/H3N2 Virus. Journal of Infectious Diseases, 2009, 199, 180-183.	1.9	37

#	Article	IF	Citations
19	Infections by Human Coronavirus-NL in Hospitalized Children. Pediatric Infectious Disease Journal, 2005, 24, 1045-1048.	1.1	35
20	Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine, 2011, 29, 1359-1363.	1.7	32
21	Replication and Immunogenicity of Swine, Equine, and Avian H3 Subtype Influenza Viruses in Mice and Ferrets. Journal of Virology, 2013, 87, 6901-6910.	1.5	30
22	Evolution of Oseltamivir Resistance Mutations in Influenza A(H1N1) and A(H3N2) Viruses during Selection in Experimentally Infected Mice. Antimicrobial Agents and Chemotherapy, 2014, 58, 6398-6405.	1.4	26
23	Combination Therapy with Oseltamivir and Favipiravir Delays Mortality but Does Not Prevent Oseltamivir Resistance in Immunodeficient Mice Infected with Pandemic A(H1N1) Influenza Virus. Viruses, 2018, 10, 610.	1.5	24
24	Evaluation of Serological Diagnostic Methods for the 2009 Pandemic Influenza A (H1N1) Virus. Vaccine Journal, 2011, 18, 520-522.	3.2	19
25	In vitro Susceptibility of Geographically and Temporally Distinct Zika Viruses to Favipiravir and Ribavirin. Antiviral Therapy, 2017, 22, 613-618.	0.6	19
26	The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 2563-2574.	1.7	18
27	Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets. Antiviral Therapy, 2011, 16, 775-779.	0.6	16
28	In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. Viruses, 2020, 12, 1139.	1.5	16
29	Activity of the Oral Neuraminidase Inhibitor A-322278 against the Oseltamivir-Resistant H274Y (A/H1N1) Influenza Virus Mutant in Mice. Antimicrobial Agents and Chemotherapy, 2009, 53, 791-793.	1.4	14
30	Synergistic PA and HA mutations confer mouse adaptation of a contemporary A/H3N2 influenza virus. Scientific Reports, 2019, 9, 16616.	1.6	13
31	Preclinical and clinical developments for combination treatment of influenza. PLoS Pathogens, 2022, 18, e1010481.	2.1	13
32	A Live Attenuated Equine H3N8 Influenza Vaccine Is Highly Immunogenic and Efficacious in Mice and Ferrets. Journal of Virology, 2015, 89, 1652-1659.	1.5	11
33	Infectivity of healthcare workers diagnosed with coronavirus disease 2019 (COVID-19) approximately 2 weeks after onset of symptoms: A cross-sectional study. Infection Control and Hospital Epidemiology, 2022, 43, 102-104.	1.0	10
34	A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets. Journal of Virology, 2015, 89, 6907-6917.	1.5	9
35	Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses. Journal of Virology, 2017, 91, .	1.5	9
36	Antiviral effect of honey extract Camelyn against SARS-CoV-2. Journal of Advanced Biotechnology and Experimental Therapeutics, 2021, 4, 290.	0.4	9

#	Article	IF	Citations
37	In vitro and in vivo evidence of a potential A(H1N1)pdm09 antigenic drift mediated by escape mutations in the haemagglutinin Sa antigenic site. Journal of General Virology, 2017, 98, 1224-1231.	1.3	9
38	Predominant role of IPS-1 over TRIF adaptor proteins in early innate immune response against Zika virus in mice. Journal of General Virology, 2018, 99, 209-218.	1.3	8
39	A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection. Nanomedicine: Nanotechnology, Biology, and Medicine, 2022, 44, 102584.	1.7	7
40	Seroconversion to Seasonal Influenza Viruses after A(H1N1)pdm09 Virus Infection, Quebec, Canada. Emerging Infectious Diseases, 2012, 18, 1132-4.	2.0	6
41	Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses. Antiviral Research, 2018, 154, 110-115.	1.9	6
42	ISCOM-like Nanoparticles Formulated with Quillaja brasiliensis Saponins Are Promising Adjuvants for Seasonal Influenza Vaccines. Vaccines, 2021, 9, 1350.	2.1	6
43	Zika Virus Isolation, Purification, and Titration. Methods in Molecular Biology, 2020, 2142, 9-22.	0.4	5
44	Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors. Antiviral Research, 2022, 200, 105280.	1.9	5
45	Epigallocatechin Gallate and Isoquercetin Synergize With Remdesivir to Reduce SARS-CoV-2 Replication In Vitro. Frontiers in Virology, 0, 2, .	0.7	5
46	Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus. Microorganisms, 2020, 8, 1968.	1.6	4
47	Replication and transmission of an influenza A(H3N2) virus harboring the polymerase acidic I38T substitution, in guinea pigs.. Journal of General Virology, 2021, 102, .	1.3	3
48	Influenza B viruses isolated in Uruguay during the 2002â€“2005 seasons: Genetic relations and vaccine strain match. Virus Research, 2007, 123, 100-104.	1.1	1
49	An addition to treatment options for avian influenza A H5N1?. Lancet Infectious Diseases, The, 2015, 15, 251-253.	4.6	1
50	97. Competition Experiments for the Baloxavir-Resistant I38T Influenza A Mutant. Open Forum Infectious Diseases, 2019, 6, S9-S9.	0.4	0